Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2022 08:00 ET | Source: Apexigen

Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference

SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
August 01, 2022 08:00 ET | Source: Apexigen

Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company

-Common stock of Apexigen to commence trading on the Nasdaq Capital Market today under the ticker symbol “APGN”- -Clinical pipeline includes multiple Phase 2 studies of sotigalimab, a CD40 agonist...
July 18, 2022 18:42 ET | Source: Apexigen

Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the Proposed Business Combination

SAN CARLOS, Calif. and NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- On March 18, 2022 Brookline Capital Acquisition Corp. (“BCAC”), a life-science focused Special Purpose Acquisition Company (“SPAC”)...
July 11, 2022 08:00 ET | Source: Apexigen

Apexigen to Participate in the Brookline Capital Markets Newport Symposium

SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
June 29, 2022 16:05 ET | Source: Apexigen

Apexigen Announces Board Appointment and New Chair

SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen” or the “Company”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the...
June 08, 2022 08:00 ET | Source: Apexigen

Apexigen Appoints William Duke as Chief Financial Officer

SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
June 06, 2022 08:00 ET | Source: Apexigen

Apexigen Announces Nature Medicine Publication and ASCO Presentation on the Phase 2 PRINCE Trial Showcasing Distinct Biosignatures in Metastatic Pancreatic Cancer Patients Treated with Sotigalimab and/or Nivolumab in Combination with Chemotherapy

- Data from the Parker Institute for Cancer Immunotherapy and Cancer Research Institute multi-center Phase 2 PRINCE trial demonstrated that novel circulating and tumor biomarkers may be predictive of...
May 09, 2022 08:00 ET | Source: Apexigen

Apexigen to Host Investor Day on Antibody Therapeutic Pipeline and Unique APXiMAB™ Platform

SAN CARLOS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (“Apexigen”), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer...
April 12, 2022 16:35 ET | Source: Apexigen

Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients with Metastatic Melanoma Presented at the AACR Annual Meeting 2022

-The combination of intratumoral sotigalimab and systemic pembrolizumab induced broad innate and adaptive immune activation in local and distant tumors- -Oral presentation on April 12, 2022 at 3:35...
April 07, 2022 08:00 ET | Source: Apexigen

Apexigen Announces That New Data From Phase 2 Trial Evaluating its CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma Will Be Presented at the AACR Annual Meeting 2022

SAN CARLOS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for...